Logo image of ARDS

ARIDIS PHARMACEUTICALS INC (ARDS) Stock Fundamental Analysis

NASDAQ:ARDS - Nasdaq - US0403341045 - Common Stock - Currency: USD

0.3101  +0.05 (+17.91%)

After market: 0.2619 -0.05 (-15.54%)

Fundamental Rating

2

Overall ARDS gets a fundamental rating of 2 out of 10. We evaluated ARDS against 562 industry peers in the Biotechnology industry. ARDS has a bad profitability rating. Also its financial health evaluation is rather negative. ARDS is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ARDS had negative earnings in the past year.
ARDS had a negative operating cash flow in the past year.
In the past 5 years ARDS always reported negative net income.
ARDS had a negative operating cash flow in each of the past 5 years.
ARDS Yearly Net Income VS EBIT VS OCF VS FCFARDS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -10M -20M -30M -40M

1.2 Ratios

ARDS has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ARDS Yearly ROA, ROE, ROICARDS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 200 -200 400 -400 -600 -800

1.3 Margins

ARDS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARDS Yearly Profit, Operating, Gross MarginsARDS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -1K -2K -3K

More info and screens

0

2. Health

2.1 Basic Checks

ARDS does not have a ROIC to compare to the WACC, probably because it is not profitable.
ARDS has more shares outstanding than it did 1 year ago.
The debt/assets ratio for ARDS has been reduced compared to a year ago.
ARDS Yearly Shares OutstandingARDS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M
ARDS Yearly Total Debt VS Total AssetsARDS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -43.31, we must say that ARDS is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ARDS (-43.31) is worse than 96.94% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -43.31
ROIC/WACCN/A
WACC8.46%
ARDS Yearly LT Debt VS Equity VS FCFARDS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 10M -10M 20M -20M

2.3 Liquidity

ARDS has a Current Ratio of 0.19. This is a bad value and indicates that ARDS is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of ARDS (0.19) is worse than 99.15% of its industry peers.
A Quick Ratio of 0.19 indicates that ARDS may have some problems paying its short term obligations.
The Quick ratio of ARDS (0.19) is worse than 99.15% of its industry peers.
Industry RankSector Rank
Current Ratio 0.19
Quick Ratio 0.19
ARDS Yearly Current Assets VS Current LiabilitesARDS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 53.11% over the past year.
ARDS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 9.70%.
The Revenue has been growing by 29.16% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)53.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.92%
Revenue 1Y (TTM)9.7%
Revenue growth 3Y44.71%
Revenue growth 5Y29.16%
Sales Q2Q%-8.85%

3.2 Future

Based on estimates for the next years, ARDS will show a very strong growth in Earnings Per Share. The EPS will grow by 40.36% on average per year.
The Revenue is expected to grow by 145.96% on average over the next years. This is a very strong growth
EPS Next Y71.9%
EPS Next 2Y46.13%
EPS Next 3Y40.36%
EPS Next 5YN/A
Revenue Next Year1609.12%
Revenue Next 2Y334.44%
Revenue Next 3Y225.86%
Revenue Next 5Y145.96%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ARDS Yearly Revenue VS EstimatesARDS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M 250M
ARDS Yearly EPS VS EstimatesARDS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 0 -5 -10 -15 -20

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ARDS. In the last year negative earnings were reported.
The Price/Forward Earnings ratio is 1.17, which indicates a rather cheap valuation of ARDS.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ARDS indicates a rather cheap valuation: ARDS is cheaper than 99.66% of the companies listed in the same industry.
ARDS's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 21.27.
Industry RankSector Rank
PE N/A
Fwd PE 1.17
ARDS Price Earnings VS Forward Price EarningsARDS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARDS Per share dataARDS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

ARDS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ARDS's earnings are expected to grow with 40.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.13%
EPS Next 3Y40.36%

More info and screens

0

5. Dividend

5.1 Amount

ARDS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARIDIS PHARMACEUTICALS INC

NASDAQ:ARDS (7/18/2023, 8:14:23 PM)

After market: 0.2619 -0.05 (-15.54%)

0.3101

+0.05 (+17.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)06-08 2023-06-08/amc
Earnings (Next)08-14 2023-08-14/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners20.6%
Ins Owner Change0%
Market Cap11.23M
Analysts80
Price Target10.2 (3189.26%)
Short Float %0.01%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-43.47%
Min EPS beat(2)-43.47%
Max EPS beat(2)-43.47%
EPS beat(4)0
Avg EPS beat(4)-283.27%
Min EPS beat(4)-635.29%
Max EPS beat(4)-43.47%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)285.7%
Min Revenue beat(2)285.7%
Max Revenue beat(2)285.7%
Revenue beat(4)1
Avg Revenue beat(4)31.22%
Min Revenue beat(4)-97.26%
Max Revenue beat(4)285.7%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)66.67%
PT rev (3m)66.67%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)33.33%
EPS NY rev (3m)33.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)47.06%
Revenue NY rev (3m)47.06%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 1.17
P/S 3.76
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.96
EYN/A
EPS(NY)0.27
Fwd EY85.52%
FCF(TTM)-0.64
FCFYN/A
OCF(TTM)-0.63
OCFYN/A
SpS0.08
BVpS-0.77
TBVpS-0.77
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.77%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.19
Quick Ratio 0.19
Altman-Z -43.31
F-Score4
WACC8.46%
ROIC/WACCN/A
Cap/Depr(3y)82.04%
Cap/Depr(5y)107.8%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)53.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.92%
EPS Next Y71.9%
EPS Next 2Y46.13%
EPS Next 3Y40.36%
EPS Next 5YN/A
Revenue 1Y (TTM)9.7%
Revenue growth 3Y44.71%
Revenue growth 5Y29.16%
Sales Q2Q%-8.85%
Revenue Next Year1609.12%
Revenue Next 2Y334.44%
Revenue Next 3Y225.86%
Revenue Next 5Y145.96%
EBIT growth 1Y33.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-11.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.29%
OCF growth 3YN/A
OCF growth 5YN/A